Atrial Fibrillation
Conditions
Brief summary
Atrial fibrillation and inflammation are strongly correlated. The aim of this study is to evaluate whether inflammation markers (alpha Defensin) predict maintenance of sinus rhythm following cardioversion. A secondary aim is to evaluate the role of Colchicine, an anti-inflammatory medication, in reducing the recurrence rate of atrial fibrillation.
Interventions
Administration of Colchicine at a dose of 0.5mg 2x a day for six months.
PROCEDURECardioversion
Electrical or pharmacologic restoration of sinus rhythm
Sponsors
Hillel Yaffe Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Investigator and participants will be blinded regarding levels of anti-inflammatory markers
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Atrial fibrillation * Candidate for cardioversion
Exclusion criteria
* Colchicine allergy * Hepatic or renal failure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence of atrial fibrillation | 12 months | Atrial fibrillation recurrence rates over the next 12 months will be determined based on medical records and ECG documentation between treatment group (Colchicine) and control group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Alpha Defensin levels in patients with recurrence of atrial fibrillation | 12 months | Alpha Defensin levels will be measured in patients with recurrence of atrial fibrillation and compared to levels in patients without recurrence. |
Countries
Israel
Contacts
Primary ContactAsaf Danon, MD, MSC
Outcome results
None listed